PUNE, India, September 23, 2016 /PRNewswire/ --
RnRMarketResearch.com announces availability of "EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025" 2016 market research providing an overview of the risk factors, comorbidities, and the global and historical trends for ACS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast from 2015-2025 for the diagnosed prevalent cases of ACS, segmented by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, segmented by sex and ACS type (STEMI, NSTEMI, and UA).
Complete report on Acute Coronary Syndrome Market Research with 13 market data tables and 11 figures, spread across 79 pages is available at http://www.rnrmarketresearch.com/epicast-report-acute-coronary-syndrome-epidemiology-forecast-to-2025-market-report.html .
Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person's symptoms, changes in the ST tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.
The acute coronary syndrome (ACS) market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022, at a relatively strong compound annual growth rate of 4.6%. The launch of several new lipid targeting therapies which offer clinical effectiveness for statin intolerant patients and patients who require additional lowering of low-density lipoprotein C (LDL-C) in combination to statin therapy, will drive the ACS market
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=692175 .
Epidemiologists forecast that in the 7MM, the diagnosed prevalent cases of ACS will grow from 25.45 million cases in 2015 to 30.62 million cases in 2025, at an Annual Growth Rate (AGR) of 2.03%. Throughout the forecast period, the diagnosed prevalent cases of ACS in the US will constitute the highest proportion in the 7MM at approximately 54%. In the 7MM, the diagnosed prevalent cases of ACS will be higher in men (61.81%) and in the age group older than 65 years (62.84%). STEMI, NSTEMI, and UA will constitute approximately 25%, 40%, and 35% of the diagnosed prevalent cases of ACS in the 7MM. In the 7MM, epidemiologists project ACS hospitalizations to increase from 1.63 million cases in 2015 to 1.71 million cases in 2025 at an AGR of 0.51%.
The US constitutes around 40% of the total hospitalized ACS cases in the 7MM for the year 2015 and will be the market with the highest number of cases during the forecast period. In 2015, the majority of the ACS hospitalizations occurred in men (62.85%) and in the age group older than 65 years (69.34%). In the year 2015, about 29% of the ACS cases in the 7MM were STEMI, 44% were NSTEMI, and 25% were UA.
The ACS EpiCast report allows readers to develop business strategies by understanding the trends shaping and driving the global ACS market, quantify patient populations in the global ACS market to improve product design, pricing, and launch plans as well as organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ACS therapeutics in each of the markets covered.
Another newly published market research report titled on Atrial Fibrillation - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are ARCA biopharma, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Cardiome Pharma Corp., Daiichi Sankyo Company, Limited, Dong-A Socio Holdings Co. Ltd., Gilead Sciences, Inc., Laboratoires Pierre Fabre SA, Nissan Chemical Industries, Ltd., OMEICOS Therapeutics GmbH, Otsuka Holdings Co., Ltd. and Xention Limited. Atrial Fibrillation Pipeline market research report of 95 pages is available at http://www.rnrmarketresearch.com/atrial-fibrillation-pipeline-review-h2-2016-market-report.html .
Explore more reports on Cardiovascular therapeutics.
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.
2nd floor, Metropole,
Next to Inox theatre,
Bund garden road,
+1 888 391 5441
SOURCE RnR Market Research